Zobrazeno 1 - 10
of 14
pro vyhledávání: '"José Miramón"'
Autor:
Angelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, Carmen Crespo, Cesar Mendiola, Rocío López-Vacas, Julia Berges-Soria, Isabel Álvarez López, Mireia Margeli, Juan L Bayo Calero, Xavier González Farre, Ana Santaballa, Eva M Ciruelos, Ruth Afonso, Juan Lao, Gustavo Catalán, José V Álvarez Gallego, José Miramón López, Francisco J Salvador Bofill, Manuel Ruiz Borrego, Enrique Espinosa, Juan A Fresno Vara, Pilar Zamora
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e109611 (2014)
BackgroundTrastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progr
Externí odkaz:
https://doaj.org/article/96570f731e5b47eda63fe7f906eaa872
Autor:
Mariano Provencio, Paloma Martín, José Gómez-Codina, Carmen Bellas, Jesús Alfaro, José Miramón, Fernando Franco, Isidro Machado, Carmen Illueca, Miguel A. Piris, Julia González-Rincón, Margarita Sánchez-Beato, Lucia Pedrosa, Javier Lavernia, Juan F. García, Delvys Rodriguez-Abreu
Publikováno v:
Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid
Consejería de Sanidad de la Comunidad de Madrid
Oncotarget
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Consejería de Sanidad de la Comunidad de Madrid
Oncotarget
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
// Fernando Franco 1, 2 , Julia Gonzalez-Rincon 3, 4 , Javier Lavernia 2, 5 , Juan F. Garcia 6 , Paloma Martin 4, 7 , Carmen Bellas 4, 7 , Miguel A. Piris 4, 8 , Lucia Pedrosa 3 , Jose Miramon 2, 9 , Jose Gomez-Codina 2, 10 , Delvys Rodriguez-Abreu 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea50c535d5f5fa164e1d832803e4a664
https://hdl.handle.net/10668/19446
https://hdl.handle.net/10668/19446
Autor:
Jesús Alfaro, José Miramón, José Gómez-Codina, Rut Álvarez, Javier Lavernia, Esteban Nogales, Mariano Provencio, Francisco Ramon Garcia Arroyo, David Aguiar-Bujanda, Natividad Martínez, Fernando Fabio Franco Pérez, Francisco Menarguez, Mayte Delgado, Maria Torrente, Miguel Ángel Marín, Ana Royuela, Delvys Rodriguez Abreu, Cristina Quero, Josep Gumá, Marta Llanos
Publikováno v:
RUNA. Repositorio da Consellería de Sanidade e Sergas
Servizo Galego de Saúde (SERGAS)
Servizo Galego de Saúde (SERGAS)
We reviewed 55 patients diagnosed with primary breast lymphoma, stages IE and IIE, in 16 Spanish institutions. Of the 55 cases, 96.4% corresponded to non-Hodgkin lymphoma. Results of 5-year progression-free and overall survival were 73% and 76%, resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::358fe419202801d0026ac6b2e4a4c94e
http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152265016305602/pdf
http://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152265016305602/pdf
Autor:
José Antonio Carbajal Medina, Emilio Alba, Maria-Isabel Sáez, Nuria Ribelles, José Miramón, Pedro Sánchez-Rovira, Vanesa de Luque, Alfonso Sánchez-Muñoz, Luis Vicioso, L. Perez-Villa, Laura Garcés Medina, Diego Pérez, Alicia Román-Jobacho, Cesar L. Ramirez-Tortosa
Publikováno v:
Oncology. 83:228-233
Aim: The aim of this study was to assess the molecular subtype profiles of male breast cancer (MBC) and subsequent clinical outcome using a validated 6-marker immunohistochemical panel. Methods: A total of 43 cases of MBC were examined retrospectivel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07a4f8213e26719dbc8a75af2413b7d6
https://doi.org/10.1159/000341537
https://doi.org/10.1159/000341537
Autor:
Ana Santaballa, Juan Ángel Fresno Vara, José Miramón López, Luis Manso, Cesar Mendiola, J. Lao, C. Crespo, Angelo Gámez-Pozo, Julia Berges-Soria, Mireia Margeli, Pilar Zamora, Gustavo Catalan, Francisco Javier Salvador Bofill, Ruth Afonso, Eva Ciruelos, Enrique Espinosa, Juan Lucas Bayo Calero, Isabel Álvarez López, Ramon Maria Perez Carrion, Xavier Farré, Manuel Ruiz Borrego, Rocío López-Vacas, Jose Valero Alvarez Gallego
Publikováno v:
Plos One
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
PLoS ONE, Vol 9, Iss 10, p e109611 (2014)
PLoS ONE
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
PLoS ONE, Vol 9, Iss 10, p e109611 (2014)
PLoS ONE
Background: Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10e55f42a5458b7e2a20cdaf9c45d6cb
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8620
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8620
Autor:
Antonia Márquez, José Miramón, Lorenzo Alonso, Inmaculada Ruiz, Antonio Rueda, Isabel Sevilla, Nuria Ribelles, Emilio Alba
Publikováno v:
Breast Cancer Research and Treatment. 66:33-39
Background. Prognostic factors in metastatic breast cancer continue to be identified. Previous adjuvant chemotherapy appeared to have poor prognosis in some studies but, despite this, the prior use of anthracyclines in the adjuvant setting has not be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1a6d9e7efa0872ac105b67a7ef428ea
https://doi.org/10.1023/a:1010616532332
https://doi.org/10.1023/a:1010616532332
Autor:
Mair Abehsera, Manuel Abarca, José Miramón, Araceli González-Valentín, Emilio Alba, Lorenzo Alonso, P. González-Santos
Publikováno v:
Revista de Oncología. 2:202-206
Objetivos Conocer el porcentaje de tratamiento conservador del cancer de marna en estadios I y II en un area geografica, la variabilidad de indicacion entre diferentes centros y los posibles factores relacionados.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2f18680fc18bc06749d500192e41097
https://doi.org/10.1007/bf02979555
https://doi.org/10.1007/bf02979555
Autor:
César A. Rodríguez, Salvador Menjón, José Miramón, Rous de Castellar, Christian Rolfo, J. A. Gasquet, Joan Carulla, Pilar García-Alonso, Nieves Díaz, Ana Magro
Publikováno v:
Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 10(11)
Fatigue is a cancer-related symptom with great impact on patients' daily lives, but often not discussed with their oncologists. This survey explored functional and psychological fatigue impact among different cancer symptoms according to patient's pe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3638580300127adf3d3f7ddbf5e14caf
https://pubmed.ncbi.nlm.nih.gov/19015072
https://pubmed.ncbi.nlm.nih.gov/19015072
Autor:
Antonia Márquez, Marta Llanos, A. Rueda Domínguez, M. A. de las Nieves, José Miramón, Emilio Alba, José R. Herrero, Josep Gumá
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 15(12)
Background Chemotherapy with ABVD (doxorubicin, bleomycin, vinblastine and darcarbacine) schedule is the standard treatment for advanced Hodgkin's lymphoma. Certain facts, including a low toxicity compared with MOPP/ABV (mechlorethamine, vincristine,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b8d1dd3cadcdcd3b4c05ddfdcd12a0
https://pubmed.ncbi.nlm.nih.gov/15550585
https://pubmed.ncbi.nlm.nih.gov/15550585
Autor:
Antonia Márquez, Miguel A. De Las Nieves, José Miramón, Isabel Sevilla, Emilio Alba, Nuria Ribelles, Josep Guma, Antonio Rueda
Publikováno v:
Leukemialymphoma. 41(3-4)
The purpose of this study was to determine the effect of granulocyte colony-stimulating factor (filgrastim, G-CSF) for maintenance of chemotherapy dose-intensity in patients with stage I or II Hodgkin's lymphoma treated with six cycles of doxorubicin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b35ba9bac43a5c239883ffeb63d0c54
https://pubmed.ncbi.nlm.nih.gov/11378548
https://pubmed.ncbi.nlm.nih.gov/11378548